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Summary
Background To achieve yaws eradication, the use of the new WHO strategy of initial mass treatment with azithromycin 
and surveillance twice a year needs to be extended everywhere the disease occurs. However, the geographic scope of 
the disease is unknown. We aimed to synthesise published and unpublished work to update the reported number of 
people with yaws at national and subnational levels and to estimate at-risk populations.
Methods We searched PubMed and WHO databases to identify published data for prevalence of active and latent 
yaws from Jan 1, 1990, to Dec 31, 2014. We also searched for ongoing or recently completed unpublished studies 
from the WHO yaws surveillance network. We estimated yaws prevalence (and 95% CIs). We collected yaws 
incidence data from oﬃ  cial national surveillance programmes at the ﬁ rst administrative level from Jan 1, 2010, to 
Dec 31, 2013, and we used total population data at the second administrative level to estimate the size of at-risk 
populations.
Findings We identiﬁ ed 103 records, of which 23 published articles describing 27 studies and four unpublished studies 
met the inclusion criteria. Prevalence of active disease ranged from 0·31% to 14·54% in yaws-endemic areas, and 
prevalence of latent yaws ranged from 2·45% to 31·05%. During 2010–13, 256 343 yaws cases were reported to WHO 
from 13 endemic countries, all of which are low-income and middle-income countries. 215 308 (84%) of 256 343 cases 
reported to WHO were from three countries—Papua New Guinea, Solomon Islands, and Ghana. We estimated that, 
in 2012, over 89 million people were living in yaws-endemic districts.
Interpretation Papua New Guinea, Solomon Islands, and Ghana should be the focus of initial eﬀ orts at implementing 
the WHO yaws eradication strategy. Community-based mapping and active surveillance must accompany the 
implementation of yaws eradication activities.
Funding None.
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which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly 
cited. In any use of this article, there should be no suggestion that WHO endorses any speciﬁ c organisation, products or 
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Introduction
Yaws is a neglected tropical disease caused by 
Treponema pallidum subspecies pertenue.1 This bacterium 
causes a chronic relapsing non-venereal treponematosis, 
characterised by highly contagious primary and 
secondary cutaneous lesions and non-contagious tertiary 
destructive lesions of the bones. The infection can 
become latent at any time, with only serological evidence 
of infection, and relapses can occur for up to 5–10 years. 
The ratio of clinically apparent to latent cases has been 
estimated to be as high as 1:6.1
In 2012, WHO launched a new initiative to eradicate 
yaws by 2020.2 Undertaking surveys and mapping the 
disease at a community level and immediately treating 
the entire endemic community with single-dose 
azithromycin3 is recommended.2 The eﬃ  cacy of this 
approach has been shown in a study of mass treatment 
in Papua New Guinea.4 A key principle inherent in an 
eradication campaign is the need to intervene everywhere 
the disease occurs. However, the present geographic 
extent of yaws is incompletely known, because yaws is 
not a notiﬁ able disease in many aﬀ ected countries. To 
guide the WHO eradication programme, a better 
knowledge of yaws epidemiology is needed.
Data that can be used to identify the burden of yaws in 
a community include the prevalence of active infectious 
yaws (ie, ulcers or papilloma), which shows the intensity 
of yaws transmission, and the prevalence of latent yaws 
(ie, seropositivity in healthy individuals), which shows 
the extent of latent or hidden infection in the community. 
Clinical surveys for active yaws lesions can be done 
without any sophisticated laboratory test through 
interviews and physical examinations, whereas 
serological tests measuring yaws antibody (treponemal 
and non-treponemal) are needed for surveys of latent 
disease.5 Another important source of information is 
national routine surveillance data, which allow estimation 
of the incidence of yaws at country and regional levels; 
countries report the number of cases at the ﬁ rst 
administrative level.
In this study, we undertook a systematic review of 
published and unpublished work to improve our 
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understanding of yaws epidemiology stratiﬁ ed by 
country, and to provide an update on the number of 
people with active yaws to estimate at-risk populations in 
endemic countries.
Methods
Search strategy and selection criteria
We did a systematic review to identify all relevant 
studies that examined yaws prevalence and incidence. 
We searched PubMed and WHO databases for (“yaws” 
OR “treponematosis” AND “prevalence” OR 
“incidence”) OR (“yaws” AND [each individual previous 
and current yaws-endemic country]6). We consulted the 
Department for the Control of Neglected Tropical 
Diseases at WHO regarding previous and present 
yaws-endemic countries.6 We limited the search to 
studies published between Jan 1, 1990, and Dec 31, 
2014. This period covers studies published since the 
last systematic review of yaws epidemiology, which was 
published in 1992.7 No language restrictions were set 
for searches. We hand-searched the reference lists of 
all recovered documents for additional references. We 
also searched for ongoing or recently completed 
but unpublished studies from the WHO yaws 
surveillance network.
We included studies if they investigated active or 
latent yaws prevalence or incidence. Studies on active 
yaws had to meet the surveillance case deﬁ nition 
provided by WHO:8 a person with a history of residence 
in an aﬀ ected area who presents with signs of clinically 
active yaws, consisting of chronic skin ulcers, multiple 
papillomata, squamous macules, bone or joint lesions, 
or plantar hyperkeratosis. For latent yaws seroprevalence 
studies, we deemed serological test rapid plasma reagin 
titres of at least 1:2 and venereal disease research 
laboratory titres of at least 1:2 as acceptable evidence of 
untreated latent infection. Use of the treponemal test 
(T pallidum haemagglutination assay, T pallidum particle 
agglutination assay, and the ﬂ uorescent treponemal 
antibody absorption) alone was not suﬃ  cient evidence 
of latent infection because people who have had yaws at 
any time will test positive for life, even after successful 
treatment.
Procedures
We calculated the number of people with active disease at 
the ﬁ rst administrative level (eg, province, region, and 
prefecture) between Jan 1, 2010, and Dec 31, 2013. First, 
whenever possible, we obtained the country estimates of 
yaws cases at the ﬁ rst administrative level from the latest 
national reporting ﬁ gures provided to WHO.6 Second, for 
countries for which no recent data were available, we 
contacted yaws control programme managers to request 
oﬃ  cial national routine surveillance data. To estimate the 
maximum population at risk of yaws, we made 
calculations at the second administrative level (eg, 
district, department, and regency). We contacted yaws 
control programme managers to request data on the 
proportion of second-administrative level regions that 
reported yaws cases in 2012. We summed the population 
living in endemic districts using the 2012 reported 
populations.
Statistical analysis
For all qualifying studies, we extracted data on study 
country, sample size, diagnostic test used, number of 
people with latent or active yaws, and age range. We 
undertook descriptive analyses of the extracted data. 
Prevalence estimates are presented for each study with 
95% CIs on the basis of binomial distribution. We did 
not undertake quantitative meta-analyses because the 
studies we identiﬁ ed did not sample populations at 
Figure 1: Selection of eligible articles
99 articles identified by database search 4 additional records identified through other sources 
 (eg, yaws surveillance network)
103 records screened
55 full-text records assessed for eligibility
48 articles excluded after review of abstracts
 20 reviews or editorials
 12 only provided data on other treponemal diseases
 6 only provided data on other infectious diseases
 3 only provided data on unrelated ulcerative diseases
 4 only provided immunology or genetic data
 3 in non-human primates
28 articles excluded after review of full text
 12 reviews of data presented elsewhere
 5 clinical studies of non-epidemiological factors
 3 diagnostic studies without epidemiological data
 3 therapeutic studies without epidemiological data
 5 did not meet inclusion criteria 27 studies included in qualitative 
analyses 
 23 published articles 
(describing 27 studies) 
 4 unpublished studies 
(describing 4 studies)
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random and hence the estimates are not representative 
for a broader geographical area. All statistical analyses 
were done using Stata version 13.1.
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
Year of 
study
Country Location Schoolchildren 
or community 
survey
Case ascertainment Cases (sample 
size)
Prevalence, % (95% CI)
Africa
Active yaws assessment
Tabah et al (2012; Tabah EN, personal 
communication)
2012 Cameroon Lomié, Zoubalot, 
Messok
Community Clinical 97 (1075) 9·02 (7·38–10·90)
Herve et al (1992)9 1990 Central African 
Republic
Lobaye School children VDRL and TPHA 12 (213) 5·63 (2·94–9·63)
Boua et al (2012; Boua B, personal 
communication)
2012 Central African 
Republic
Lobaye, Sangha-
Mbaeré
School children Clinical 230 (2030) 11·33 (9·98–12·79)
Coldiron et al (2013)10 2012 Republic of Congo Bétou, Ebyellé Community RDT 183 (6215) 2·94 (2·54–3·40)
Konan et al (2007)13 2004 Côte d’Ivoire Adzopé Community RPR 11 (2182) 0·50 (0·25–0·90)
Gerstl et al (2009)14 2005 Democratic Republic 
of the Congo
Wasolo Community RPR and TPHA 56 (1176) 4·76 (3·62–6·14)
Nsiire et al (2011; Nsiire A, personal 
communication)
2011 Ghana Volta Region School children ND 3159 (125 364) 2·52 (2·43–2·61)
Akogun (1999)16 1998 Nigeria Garkida Community Clinical 64 (1523) 4·20 (3·25–5·33)
Latent yaws assessment
Ayelo et al (2012; Ayelo G, personal 
communication)
2012 Benin Toﬀ o, Zé, Allada School children RPR 22 (900) 2·44 (1·54–3·68)
Herve et al (1992)9 1990 Central African 
Republic
Lobaye School children VDRL and TPHA 42 (213) 19·72 (14·60–25·70)
Western Paciﬁ c
Active yaws assessment
Backhouse et al (1998)20 1988 Papua New Guinea Karkar Island School children VDRL, FTA-Abs, and TPHA 26 (632) 4·11 (2·70–5·97)
Manning and Ogle (2002)21 2001 Papua New Guinea Port Moresby–NCD School children VDRL and TPHA 33 (227) 14·54 (10·22–19·81)
Harris et al (1991)24 1989 Vanuatu Tanna Island Community VDRL 464 (20 200) 2·30 (2·09–2·51)
Latent yaws assessment
de Noray et al (2003)25 2001 Vanuatu Santo Island Community VDRL 57 (273) 20·88 (16·21–26·19)
Fegan et al (2010)26 2008 Vanuatu Tanna Island Community VDRL and TPHA 95 (306) 31·05 (25·90–36·56)
Guerrier et al (2011)27 2010 Wallis and Futuna Wallis and Futuna Community RPR and TPHA 27 (264) 10·23 (6·85–14·53)
Southeast Asia
Active yaws assessment
Noordhoek et al (1991)18 1988 Indonesia Sumatra School children VDRL, TPHA, FTA-Abs, 
TmpA EIA, and WB
114 (37 000) 0·31 (0·25–0·37)
dos Santos et al (2010)19 2007 Timor-Leste Oecusse, Bobonaro, 
Cova Lima, Atauro 
Island
Community Clinical 6 (1535) 0·39 (0·14–0·85)
Latent yaws assessment
WHO India (2006)31 2005 India Ten states School children RPR and TPHA 0 (3831) 0·00 (0·00–0·00)
The Americas
Active yaws assessment
Anselmi et al (1995)28 1993 Ecuador Santiago basin Community VDRL and FTA-Abs 16 (1118) 1·43 (0·82–2·31)
Anselmi et al (2003)29 1998 Ecuador Santiago basin Community VDRL and FTA-Abs 0 (1926) 0·00 (0·00–0·19)
Scolnik et al (2003)30 2000 Guyana Bartica School children MHA-TP 52 (1020) 5·10 (3·83–6·63)
Latent yaws assessment
Anselmi et al (1995)28 1993 Ecuador Santiago basin Community VDRL and FTA-Abs 53 (1118) 4·74 (3·57–6·16)
Anselmi et al (2003)29 1998 Ecuador Santiago basin Community VDRL and FTA-Abs 68 (1926) 3·53 (2·75–4·45)
FTA-Abs=ﬂ uorescent treponemal antibody–absorption. MHA-TP=microhaemagglutination assay–Treponema pallidum. NCD=National Capital District. ND=not documented. RDT=rapid diagnostic test. 
RPR=rapid plasma reagin. TmpA EIA=enzyme immunoassay with TmpA antigen. TPHA=T pallidum haemagglutination. VDRL=Venereal Disease Research Laboratory. WB=western blot with T pallidum 
subspecies pallidum as antigen.
Table 1: Characteristics and outcomes of the 24 included studies of active and latent yaws prevalence
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study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Our systematic review identiﬁ ed 103 records, from which 
we identiﬁ ed 23 eligible published articles9–31 that 
described 27 studies that met our inclusion criteria 
(ﬁ gure 1). We included data from an additional four 
studies identiﬁ ed from other sources (personal 
communications with country managers and yaws 
experts: Tabah EN, personal communication; Boua B, 
personal communication; Nsiire A, personal com-
munication; Ayelo G, personal communication). The 
included studies covered 18 countries. Three of these 
countries—Guyana, Nigeria, and Wallis and Futuna—
were classiﬁ ed by WHO as previously endemic countries 
with unknown status in 2012. Two countries—Ecuador 
and India—were reported to have eliminated yaws.29,31 
The remaining 13 countries were classiﬁ ed as known 
endemic countries in 2012.6
Among the 31 studies, 16 reported data on active yaws 
prevalence (table 1; Tabah EN, personal communication; 
Boua B, personal communication; Nsiire A, personal 
communication).9,10,13,14,16,18–21,24,28–30 Patients with suspected 
yaws skin lesions were further tested with syphilis 
serology, except in four studies in which diagnosis was 
made on the basis of clinical criteria only (Tabah EN, 
personal com munication; Boua B, personal 
communication).16,19 After excluding one study from 
Ecuador29 in 1998 in which no clinical cases were 
detected, prevalence of active yaws lesions ranged from 
0·31% in Sumatra, Indonesia,18 to 14·54% around the 
city of Port Moresby, Papua New Guinea.21 High 
prevalence rates were also noted in surveys done in 
tropical forests in Central Africa that were inhabited by 
indigenous populations (ie, Pygmies), including 9·03% 
Period of 
study
Country Location Target population Case 
ascertainment
New cases (at-risk 
population)
Incidence, cases per 1000 
population-years (95% CI)
Africa
Toure et al (2007)11 2000 Côte d’Ivoire Nationwide Children and adults Clinical 9212 (15 882 758) 0·58 (0·57–0·59)
Konan et al (2013)12 2011 Côte d’Ivoire Nationwide Children and adults Clinical 3343 (22 594 212) 0·15 (0·14–0·15)
Edorh et al (1994)15 1991 Togo Nationwide School children Clinical 3750 (3 787 000) 0·99 (0·96–1·02)
Nnoruka (2005)17 1999–2001 Nigeria Enugu Hospital Children and adults Clinical 0 (2871) 0·00 (0·00–1·28)
Western Paciﬁ c
Manning and Ogle (2002)21 2000–01 Papua New Guinea Port Moresby Children and adults RPR and TPHA 494 (20 000) 24·70 (22·59–26·95)
Mitja et al (2011)22 2009 Papua New Guinea Lihir Island School children RPR and TPHA 138 (5 400) 25·56 (21·51–30·12)
Ministry of Health, Solomon Islands 
(2013)23
2012 Solomon Islands Nationwide Children and adults Clinical 12 372 (515 870) 23·98 (23·57–24·40)
RPR=rapid plasma reagin. TPHA=Treponema pallidum haemagglutination.
Table 2: Characteristics and outcomes of health-facility-based active yaws incidence studies
Figure 2: Annual absolute number of yaws cases by country
Incidence given in cases per 100 000 population-years in 2010–12.
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in Cameroon (Tabah EN, personal communication), 
11·34% in the Central African Republic (Boua B, 
personal communication), 4·77% in the Democratic 
Republic of the Congo,14 and 2·95% in the Republic 
of Congo.10
Overall, eight studies reported data on the prevalence 
of latent yaws (table 1; Ayelo G, personal com-
munication).9,25–29,31 After excluding one study from 
India31 in which no seropositive cases were detected, 
prevalence of reactive serology ranged from 2·45% in 
Benin (Ayelo G, personal communication) to 31·05% in 
Tanna Island, Vanuatu.26 Seroprevalence estimates were 
high in all three studies from the western Paciﬁ c 
region.25–27 Other studies reporting high seroprevalence 
were done in Lobaye, Central African Republic 
(19·72%).9 In Ecuador, after the implementation of a 
yaws surveillance and treatment programme, serological 
surveys done in 1998 showed a low prevalence of 
reactive serology (3·54%),29 and a survey in India in 
2005 reported no sero-reactors among 3821 children 
younger than 5 years.31
Table 2 summarises health-facility-based incidence 
studies that used passive case ﬁ nding.11,12,15,17,21–23 In the 
study in Nigeria, the results for skin diseases were 
reported in 2001, mainly in adults, but no cases of yaws 
were noted.17 Among the remaining studies, incidence of 
yaws ranged between 0·15 cases per 1000 population-
years in Côte d’Ivoire11 to 25·56 per 1000 population-years 
in a highly endemic area of Papua New Guinea.22
During the 4-year period between 2010 and 2013, 
256 343 yaws cases were reported to WHO from 
11 countries and territories (ﬁ gure 2). Togo and Timor-
Leste are judged by WHO to be endemic, but did not 
report any case in the study period. Large-scale yaws 
control programmes have recently resulted in disease 
elimination in two countries (Ecuador and India).29,31 
Figure 2 shows the annual number of yaws cases in all 
countries with ongoing transmission. The reported 
number of active infections was below 300 per year in 
Benin, Cameroon, Central African Republic, Republic of 
Congo, and Democratic Republic of the Congo, but data 
were probably under-reported from all of these countries. 
215 308 (84%) of 256 343 cases reported to WHO were 
from three countries—Papua New Guinea, Solomon 
Islands, and Ghana.
Table 3 summarises the estimates of the number of 
people at risk of yaws, stratiﬁ ed by region. We estimated 
that, in 2012, 8944 8862 people were living in yaws-
endemic areas: about 46·7 million people in Africa, 
35·8 million in southeast Asia, and 7·0 million in the 
western Paciﬁ c. At-risk population estimates for Ghana, 
Côte d’Ivoire, and Indonesia might be revised down 
because not all communities in each endemic district in 
these countries are endemic for yaws.
Figure 3 shows the cumulative number of yaws cases 
from 2010 to 2013 in the WHO Africa region, shown by 
subnational regions. Six subnational regions in Ghana 
were very highly endemic (ie, >5000 cases within the 
4-year reporting period), including the Eastern, Central, 
Volta, Western, Ashanti, and Brong-Ahafo regions. In 
Côte d’Ivoire, the regions of Fromager, Sud-Bandama, 
Haut-Sassandra, and Bas-Sassandra were highly 
endemic (ie, 1000–4999 cases within the 4-year reporting 
period). The East region in Cameroon, Likouala 
department in the Republic of Congo, and Lobaye 
prefecture in Central African Republic, which are close 
to one another, were all moderately endemic 
(ie, 100–999 cases within the 4-year reporting period). 
Data from Central African Republic were limited to 
surveys in two regions and the situation of the rest of the 
country remains to be investigated.
Figure 4 shows the cumulative number of yaws cases 
in the WHO western Paciﬁ c and southeast Asia regions 
within the 4-year period, shown by subnational region. In 
Papua New Guinea, ﬁ ve provinces were very highly 
endemic (>5000 cases)—New Ireland, West New Britain, 
East New Britain, Madang, and Autonomous Region of 
Bougainville provinces—whereas seven provinces were 
highly endemic (1000–4999 cases). The Western province 
in Solomon Islands, and Tafea province in Vanuatu were 
also very highly endemic. In Indonesia, most cases were 
found in the province of Nusa Tenggara Timur, where 
13 084 cases were reported during the 4-year period. No 
recent surveillance data have been reported from Timor-
Leste, but the country is regarded as endemic according 
to WHO.
Population of 
country*
Health districts reporting 
yaws (n/N [%])
Population living in 
endemic districts
Africa
Benin† 9 364 619 2/34 (5·9%) Minimum 632 488. Total 
not known
Cameroon 22 128 420 22/179 (12·3%) 2 360 944
Central African Republic‡ 4 600 125 2/17 (11·8%) Minimum 434 521. Total 
not known
Republic of Congo 4 001 831 16/84 (19·0%) Minimum 1 555 513
Côte d’Ivoire 23 261 022 56/81(69·1%) 18 000 000
Democratic Republic of the Congo 75 507 000 ND/36 Not known§
Ghana 24 658 823 160/170 (94·1%) 23 178 000
Togo 6 191 155 2/35 (5·7%) 545 729
Western Paciﬁ c
Papua New Guinea 7 146 240 75/89 (84·3%) 6 201 393
Solomon Islands 515 870 10/10 (100%) 515 870
Vanuatu 234 023 6/6 (100%) 234 023
Southeast Asia
Indonesia 241 692 190 106/497(21·3%) 34 588 881
Timor-Leste 120 1500 13/13 (100%) 120 1500
ND=no data. *From 2012, except Ghana (2010) and Vanuatu and Indonesia (2009). †Accurate data were only available 
for two districts. The prevalence of yaws in the remaining 32 districts was not known. ‡Accurate data were only 
available for two districts. The prevalence of yaws in the remaining 22 districts was not known. §District-level data were 
not available to allow an accurate calculation of the population at risk.
Table 3: Estimates of at-risk populations living in districts judged to be endemic (second administrative 
level; 2012)
Articles
e329 www.thelancet.com/lancetgh   Vol 3   June 2015
Figure 4: Cumulative number of yaws cases by subnational regions in the WHO southeast Asia and western Paciﬁ c regions
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Figure 3: Cumulative number of yaws cases by subnational regions in the WHO Africa region
Articles
www.thelancet.com/lancetgh   Vol 3   June 2015 e330
Discussion
Our data show that about 65 000 yaws cases per year 
occurred in 13 endemic countries and that in at least 
19 countries the incidence of yaws is unknown; thus, 
there has been limited progress since the last systematic 
review on yaws epidemiology in 1992 (85 000 yaws cases 
in 33 endemic countries).7 In 1953, Hackett32 estimated 
there were 50–150 million cases of yaws in 90 countries. 
A substantial decrease in the prevalence of yaws was 
brought about by the implementation of mass treatment 
campaigns and subsequent surveillance activities in the 
1950s and 1960s. In many countries, yaws control and 
surveillance activities stopped after 1970, with a 
subsequent resurgence of yaws, particularly in parts of 
west and central Africa and in southeast Asia.7 Little 
activity to control the infection has been undertaken 
since 1990. The scarcity of political will, inadequate 
funding, and weaknesses in primary health-care 
systems in aﬀ ected countries have been the biggest 
obstacles to the reduction of the burden of yaws in the 
past two decades.
The methods proposed for assessing yaws burden have 
not changed substantially since 1953; however, unlike in 
the previous review by Hackett,32 who sent a questionnaire 
to all countries in Africa and carefully analysed the 
replies, or in the review by Meheus and Antal,7 who 
compiled original data from country reports submitted to 
WHO, we also extracted and synthesised a large amount 
of data from published studies, and complemented this 
with data from grey literature.
An important ﬁ nding of our work is that almost 85% 
of all infections occurred in three countries—Ghana, 
Papua New Guinea, and Solomon Islands.6 The results 
of individual studies in these countries, which showed 
high prevalence and incidence rates, are consistent with 
integrated surveillance data. An overall low number of 
cases have been reported in national surveillance 
programmes in other countries in central Africa.6 
However, we have shown that focal indigenous 
populations (ie, Pygmies) in the Central African 
Republic, Cameroon, Republic of Congo, and 
Democratic Republic of the Congo are aﬀ ected by yaws, 
with prevalence of active disease ranging between 3% 
and 11% (Boua B, personal communication).9,10,14 The 
main risk factor for these groups, as for in other settings 
in which yaws is highly endemic, is the scarcity of access 
to health care and poor personal hygiene.
Among the 13 known endemic countries, we estimated 
that a maximum of about 89 million people were living 
in yaws-endemic areas. In view of the focal nature of the 
disease, the size of the population at risk, in particular in 
Ghana, Côte d’Ivoire, and Indonesia, is uncertain. This 
global estimate of at-risk individuals would probably be 
revised down if community-based surveys were used to 
guide the implementation of mass treatment.
The major limitation of our study is the weakness of 
routinely reported data. Yaws is not a notiﬁ able disease and 
the use of national routine surveillance data is likely to 
result in an under estimation of the real number of cases 
because yaws predominantly occurs in rural communities 
with poor access to health facilities, whereas available data 
are primarily from health facilities. The limited reliability 
of clinical diagnoses of yaws and the recognition that other 
organisms can cause clinically similar skin lesions in 
yaws-endemic countries33,34 causes problems for clinical 
case reporting. The weakness of reported data shows the 
limitations of the present data and supports the need for 
surveys as per the WHO strategy.
We did not undertake a meta-analysis for several 
reasons. First, the studies that we included were primarily 
implemented in settings where yaws is endemic and no 
random sampling from a general population was done. 
Hence, the prevalence estimates are not representative of 
a given district, province, or an entire country. Second, 
the number of studies from each WHO region was 
limited. Third, the inclusion and diagnostic criteria 
varied markedly between studies, with both children and 
adults and both clinical and serological deﬁ nitions of 
yaws included. These factors make direct comparison of 
the survey ﬁ ndings diﬃ  cult.
The results of this systematic review contribute to the 
epidemiological knowledge needed to guide the 
preliminary estimation of resources that are necessary 
for a successful eradication programme. The inability  of 
several countries to undertake more active surveillance 
and surveys is a major obstacle to achieving the WHO 
2020 eradication target. The weaknesses of routinely 
reported data shows the need to establish a strict and 
sensitive surveillance system similar to other eradication 
programmes (eg, for Guinea worm and poliovirus) in a 
way that enables regionalisation of cases to make the 
decision about which communities need mass treatment 
and other control interventions.
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